Repaglinide insulin secretagogues

Description Results NMA

repaglinide 2 mg thrice daily (n=-9)

vs.

metformin 1 g twice daily (n=-9)

double-blind

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

repaglinide, administered preprandially three times daily (n=-9)

vs.

glibenclamide, given preprandially once or twice daily (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 14 weeks

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

repaglinide (0.5-4 mg t.i.d.) (n=211)

vs.

glyburide (1.75-10.5 mg daily) (n=109)

double-blind

Sample size: 211/109

Primary endpoint:

FU duration: 1 year

repaglinide, 1-4 mg at mealtimes (n=256)

vs.

glipizide, 5-15 mg daily (n=0)

double-blind

Sample size: 256/0

Primary endpoint:

FU duration: 1 year

repaglinide (0.5–4.0 mg at meals), (n=256)

vs.

combination of repaglinide (1–4 mg at meals) and troglitazone (200–600 mg once daily) (n=0)

open

Sample size: 256/0

Primary endpoint:

FU duration: 22 weeks

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

prestudy dose of metformin with the addition of repaglinide (n=27)

vs.

prestudy dose of metformin (n=27)

open

Parallel groups

Sample size: 27/27

Primary endpoint:

FU duration: 12 weeks

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

repaglinide (n=66)

vs.

placebo (n=33)

double-blind

Parallel groups

Sample size: 66/33

Primary endpoint:

FU duration: 18 weeks

repaglinide 1 mg (n = 140), or repaglinide 4 mg (n = 146) (n=286)

vs.

placebo (n=75)

double-blind

Sample size: 286/75

Primary endpoint:

FU duration: 24 weeks